C
Citius Oncology, Inc. (CTOR)
NCM – Real Time Price. Currency in USD
0.90
-0.00 (-0.08%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.90
-0.00 (-0.08%)
At close: May 12, 2026, 4:00 PM EDT
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
| Name | Position |
|---|---|
| Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer |
| Mr. Jaime Bartushak | Chief Financial Officer & Treasurer |
| Mr. Leonard L. Mazur | CEO, President & Executive Chairman |
| Mr. Myron Z. Holubiak | Secretary & Executive Vice Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 8-K | ea0289297-8k_citius.htm |
| 2026-04-29 | 8-K | ea0288202-8k_citius.htm |
| 2026-04-28 | 8-K | ea0288020-8k_citius.htm |
| 2026-03-31 | 8-K | ea0284321-8k_citius.htm |
| 2026-03-10 | 8-K | ea0280663-8k_citius.htm |
| 2026-03-04 | 8-K | ea0277423-8k_citius.htm |
| 2026-02-20 | POS AM | ea0277308-posam1_citius.htm |
| 2026-02-13 | 10-Q | ea0276448-10q_citius.htm |
| 2026-01-29 | DEF 14C | ea0274187-def14c_citius.htm |
| 2026-01-20 | PRE 14C | ea0273118-pre14c_citius.htm |